Evidence map›Paper›PMID 35739634›Full record

ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2022

Patient and tumour characteristics of screening-age adults diagnosed with screen-detected versus symptomatic colon cancer.

Elizabeth A Sarma, Matthew J Thompson, Erin J A Bowles, Andrea N Burnett-Hartman, Rebecca A Hubbard, Onchee Yu, Jessica Chubak

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Elizabeth A SarmaDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-7977-9015
Matthew J ThompsonDepartment of Family Medicine, University of Washington, Seattle, Washington, USA.
Erin J A BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Andrea N Burnett-HartmanKaiser Permanente Colorado Institute for Health Research, Aurora, Colorado, USA.
Rebecca A HubbardDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Onchee YuKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Jessica ChubakKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Kaiser Permanente Washington Health Research Institute · USKaiser Permanente · USNational Cancer Institute · USUniversity of Pennsylvania · USUniversity of Washington · US

Funding

Commonly Used Medications and Risk of Colorectal Cancer RecurrenceR01CA172073 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI CHUBAK, JESSICA · 2013 to 2016
$2.1M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01CN067009 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 1997
–
Cancer Research UKIntramural NIH HHS Z99 CA999999NCI NIH HHS N01 CN067009NCI NIH HHS N01 PC035142NCI NIH HHS R01 CA172073NCI NIH HHS R01CA172073NCI NIH HHS R50 CA211115NCI NIH HHS R50CA211115
6 · The paper itself

Abstract

aimInternational studies have shown that most colon cancers are diagnosed among people with symptoms, but research is limited in the United States. Here, we conducted a retrospective study of adults aged 50-85 years diagnosed with stage I-IIIA colon cancer between 1995 and 2014 in two US healthcare systems.

methodsMode of detection (screening or symptomatic) was ascertained from medical records. We estimated unadjusted odds ratios (OR) and 95% confidence intervals (CI) comparing detection mode by patient factors at diagnosis (year, age, sex, race, smoking status, body mass index [BMI], Charlson score), prediagnostic primary care utilization, and tumour characteristics (stage, location).

resultsOf 1,675 people with colon cancer, 38.4% were screen-detected, while 61.6% were diagnosed following symptomatic presentation. Screen-detected cancer was more common among those diagnosed between 2010 and 2014 versus 1995-1999 (OR 1.65, 95% CI: 1.19-2.28), and those with a BMI of 25-<30 kg/m

conclusionsMost colon cancers among screen-eligible adults were diagnosed following symptomatic presentation. Even with increasing screening rates over time, research is needed to better understand why specific groups are more likely to be diagnosed when symptomatic and identify opportunities for interventions.

Indexed as

Colonic NeoplasmsAdultDelivery of Health CareEarly Detection of CancerFemaleHumansMass ScreeningRetrospective StudiesUnited Statescolon cancerearly detectionscreeningsigns and symptoms

Identifiers

PMID35739634
PMCPMC10018485
OpenAlexW4283393866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.